InspireMD Inc. · NASDAQ:NSPR
InspireMD — Investor Presentation (March 2025)
29 slides from InspireMD's investor presentation, March 2025
Slide 1: CGuard Carotid Stent Platform for Sustained Embolic Protection
CGuard Carotid Stent Platform for Sustained Embolic Protection Nasdaq: NSPR
Slide 2: Disclaimers
Disclaimers Forward Looking Statement This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For
Slide 3: Developer of CGuard Prime Carotid Stent Platform
Developer of CGuard Prime Carotid Stent Platform Dedicated to advancing the prevention of stroke and treatment of carotid artery disease 3
Slide 4: Transforming the Carotid Intervention Market
Transforming the Carotid Intervention Market CGuard EPS Stent Platform CMS Coverage Expanded Proprietary MicroNet Technology Standard Risk and Asymptomatic Reimbursement Highly differentiated platform for treatment of carotid Enables stent-first approach to carotid revascularization artery disease a
Slide 5: Endovascular Revolution Has Arrived
Endovascular Revolution Has Arrived MicroNetTM covered CGuardTM stent platform could become the new gold standard CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL CAROTID ARTERY ANEURYSMS ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE DISEASE5 AWAITING CONVERSION TO ENDO 30% Surgical1 23% Surgical2
Slide 6: Potential $8B Global Market Opportunity
Potential $8B Global Market Opportunity Carotid procedures today are ~2.8 million primarily surgical Current Untreated People diagnosed with HGCS (Untreated) Global Market $8.0 billion 407,000 Global procedures (CEA/CAS/TCAR) to treat Current Treated HGCS (High Grade Carotid Stenosis) (1) Global Mar
Slide 7: The CGuard Difference: The Impact of MicroNet Technology
The CGuard Difference: The Impact of MicroNetTM Technology1 Approximately 2/3 of neurovascular events (stroke, TIA) occur after the carotid surgery procedure takes place2. Prevention depends on protection VS. Protruding plaque/thrombus MicroNetTM sealing plaque/ between struts thrombus against vesse
Slide 8: Long-Term Stent Performance is the Cornerstone of Our Focus
Long-Term Stent Performance is the Cornerstone of Our Focus Delivery Platform Agnostic CGuard EPS Well-positioned to capitalize on the ongoing paradigm shift toward a “stent first” approach and away from surgery CAS Agnostic to stent TCAR delivery approach (TCAR vs. CAS) Tandem Stroke 8
Slide 9: All Stents Are Not Created Equal- Varying Cell Sizes Impact Vessel Wall Coverage
All Stents Are Not Created Equal- Varying Cell Sizes Impact Vessel Wall Coverage Area Comparison (mm2) CGuard RoadSaverTM *165µ 375µ 500µ 1050µ 1900µ Closed cell stent Open cell stent ACCULINK WallStent * Bench test results may not necessarily be indicative of clinical performance. Stent images appr
Slide 10: A Picture is Worth a Thousand Words
A Picture is Worth a Thousand Words… VS Surgical Endarterectomy 90% occlusion CGuard Stent Stenting 10
Slide 11: Unmatched Foundational Data and Evidence
Unmatched Foundational Data and Evidence Company and Products Overview 11
Slide 12: PMA Trial Design (C-GUARDIANS)
PMA Trial Design (C-GUARDIANS) Prospective, multicenter international single-arm clinical trial Pivotal Study Objective Principal Investigators Evaluate the safety and efficacy of the CGuard Carotid Chris Metzger, M.D. (Ballad Health, Kingsport, TN) Stent System in the treatment of carotid artery st
Slide 13: C-GUARDIANS: 30-Day Safety Outcomes
C-GUARDIANS: 30-Day Safety Outcomes 30-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 30-day outcomes 30-day DSMI (multiple FDA trials) Intention Per 8.30% to Treat Protocol1,2 30-day DSMI 0.95% (3) 0.63% (2) 5.80% 5.80% 5.40% 5.10% 4.80% Death 0.32% (1) 0.0% (0) 3.50%
Slide 14: C-GUARDIANS: 1-Year Safety and Effectiveness Outcomes
C-GUARDIANS: 1-Year Safety and Effectiveness Outcomes Composite event rate of 30-Day Death/Stroke/MI (DSMI) or Ipsilateral stroke between days 31-365 CGUARDIANS 1-Year outcomes 30-day DSMI or Ipsilateral Stroke to 1-Year Intention to Treat Per Protocol1,2 12.20% Primary Endpoint: 30-day Death, Strok
Slide 15: CARMEN Meta-Analysis (112 Studies, 68K Patients)
CARMEN Meta-Analysis (112 Studies, 68K Patients)1 30-day and 12-month event rates by stent type (random-effect model) Terumo Gore Event FGS SGS RoadSaver/ Improvements from second- Casper (not marketed) CGuard generation stents (SGS) relative to first-generation 30-day Stroke [%] (95% CI) 3.01 (2.
Slide 16: Randomized DW-MRI Study Comparing CGuard and Acculink
Randomized DW-MRI Study Comparing CGuard and Acculink Demonstrates the Neuroprotective Effect of MicroNet DW-MRI number of cerebral lesions: 45 with CGuard vs 82 with Acculink (p= 0.03) DW-MRI total volume of cerebral lesions: 18,212 mm3 with CGuard vs 3,930 mm3 with Acculink Filters with Macroscopi
Slide 17: TCAR
TCAR Company and Products Overview 17
Slide 18: Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow
Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow InspireMD combines SwitchGuard NPS with Best-in-Class CGuard Implant 1. Transient flow reversal combined with sustained embolic prevention in transcervical revascularization of symptomatic and highly-emboligenic
Slide 19: SwitchGuard NPS (TCAR)
SwitchGuard NPS (TCAR) 80CM TCAR Market Opportunity ~3,000 TCAR-trained physicians in the U.S.1 ~30,000 TCAR procedures (~$212M) performed in the U.S. in 2024, double- digit growth projected1,2 1 Piper-Sandler model, 05/01/24 2 Piper-Sandler model, 05/01/24 19
Slide 20: The Promise of TCAR with CGuard Prime
The Promise of TCAR with CGuard Prime DW MRI study of recently symptomatic patients- Professor Nacho Leal at LINC 2024 6.7% c incidence Post-procedural DW MRI lesion 15 recently- Complete resolution in follow-up imaging at 30 days symptomatic (<14 days) patients were treated with CGuard using 0% flo
Slide 21: Corporate
Corporate Company and Products Overview 21
Slide 22: Roadmap / Milestones
Roadmap / Milestones Key Value Drivers 2025 2026 2027 CGuard Prime PMA Approval CGuard Prime CAS Market Expansion Further Commercial Expansion in the U.S Launch for CAS CGuard Prime 80 TCAR Market Expansion Global Expansion in Asia U.S Expansion Build out of U.S. HQ, Operational and CGuard Prime 80
Slide 23: Commercial Footprint
• Active selling in more than 30 countries Commercial Footprint • Over 60,000 systems sold • Average CAS Market share of 25% Signed agreement with Chinese distributor. Working toward distribution Investigational Device Exemption (IDE) trial enrollment completed Q2 Exploring expansion 2023; potential
Slide 24: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued Pending USA 19 6 Rest of World 40 17 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products IP Counsel: Kligler and Associates, P.A
Slide 25: Executive Leadership Team
Executive Leadership Team Deep industry experience and subject matter expertise Marvin Slosman Shane Gleason Craig Shore Andrea Tommosoli Chief Executive Officer Chief Commercial Officer Chief Financial Officer Chief Operating Officer • 30+ years medical device • 20+ years cardiovascular • 25+ years
Slide 26: Scientific Advisory Board (Multidisciplinary KOLs)
Scientific Advisory Board (Multidisciplinary KOLs) Sean Lyden, M.D. Chris Metzger , M.D. Kenneth Rosenfield, M.D. Adnan H. Siddiqui, M.D. Ph.D Vascular Surgeon Medical Director Interventional Professor, Vice Chairman of the Cardiologist Department of Neurosurgery Cardiologist 26
Slide 27: Transformational May 2023 Financing Up To $113.6 Million
Transformational May 2023 Financing Up To $113.6 Million To advance the company towards potential US approval and launch of CGuard EPS and other value-creating milestones • $42.2 million upfront funding • $71.4 million tied to the achievement of four milestones ($17.9 million each) each expiring upo
Slide 28: Summary Financials
Summary Financials March 11, 2025 NASDAQ Capital Markets NSPR Stock Price $2.79 Average 3 Month Volume 47.8K Shares Outstanding 29.7M Shares Outstanding with Prefunded Warrants 55.2M Market Capitalization with Prefunded Warrants $154.0M Cash Balance - December 31, 2024 $34.6M Debt - December 31, 202
Slide 29: NASDAQ Nasdaq: = NSPR NSPR
NASDAQ Nasdaq: =NSPR NSPR